FHTX - Company ID 0001822462
Foghorn Therapeutics Inc. trades as FHTX. In its fiscal 2025 annual report the company posted revenue of $30.91M, up 36.8% from the prior year and net income of -$74.28M. This page tracks Foghorn Therapeutics Inc. through 338 SEC filings, with financial statements and metrics updated as new reports are filed.
Research snapshot
Updated
With latest filings
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Next research step
Over the last 5 fiscal years Foghorn Therapeutics Inc.'s revenue grew from $430.00K to $30.91M, a compound annual growth rate of 135.1%. Net profit margin expanded from -16000.0% to -240.3% over the same period - every figure below comes from the company's audited annual filings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.
| Filing | Type | Filed |
|---|---|---|
| SCHEDULE 13G/A | - | 2026-05-15 |
| SCHEDULE 13G/A | - | 2026-05-14 |
| Quarterly report | 10-Q | 2026-05-07 |
| Major company event | 8-K | 2026-05-07 |
| SCHEDULE 13G/A | - | 2026-05-06 |
| Annual report to shareholders | ARS | 2026-04-30 |
| Proxy materials | DEFA14A | 2026-04-30 |
| Proxy statement | DEF 14A | 2026-04-30 |
The largest companies sharing Foghorn Therapeutics Inc.'s SEC industry classification (pharmaceutical preparations).
Foghorn Therapeutics Inc. reported revenue of $30.91M for fiscal year 2025, an increase of 36.8% year over year.
In its latest fiscal year Foghorn Therapeutics Inc. reported a net loss of $74.28M.